Concepedia

Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer

Yanjing Li, Yiping He, William Butler, Lingfan Xu, Yan Chang, Kefeng Lei, Yinglu Zhou, Allen C. Gao, Qingfu Zhang, Daniel Taylor,

Science Translational Medicine · 2019 · 136 citations · 28 references

DOIFull text

Open access

Concepts

Abstract

luminal cells. We demonstrate that the combination of CXCR2 inhibition and AR targeting is an effective treatment strategy in mouse xenograft models. Such a strategy has the potential to overcome therapy resistance caused by tumor cell heterogeneity.

References

28

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

Aravind Subramanian, Pablo Tamayo, Vamsi K. Mootha et al. · Proceedings of the National Academy of Sciences · 2005 · 56.7K citations · Full text

, , +12

Abiraterone and Increased Survival in Metastatic Prostate Cancer

Johann S. de Bono, Christopher J. Logothetis, Arturo Molina et al. · New England Journal of Medicine · 2011 · 4.4K citations · Full text

, , +17

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

David A. Barbie, Pablo Tamayo, Jesse S. Boehm et al. · Nature · 2009 · 4.2K citations · Full text

, , +13

Integrative Genomic Profiling of Human Prostate Cancer

Barry S. Taylor, Nikolaus Schultz, Haley Hieronymus et al. · Cancer Cell · 2010 · 3.8K citations · Full text

, , +14

Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer

Himisha Beltran, Davide Prandi, Juan Miguel Mosquera et al. · Nature Medicine · 2016 · 1.7K citations · Full text

, , +14